Zobrazeno 1 - 10
of 52
pro vyhledávání: '"35"'
Autor:
N Rueth, Karen K. Swenson, M Knaack, Janet Krueger, Barbara Susnik, P Martone, SR Baldinger, Michaela Tsai, Erin Grimm, Tamera J. Lillemoe
Publikováno v:
Cancer Research. 79:P5-10
Background: While breast cancer is rare in women ≤ age 35, patients in this age group are more frequently diagnosed with aggressive cancer subtypes and pathologic germline mutations in cancer susceptibility genes than older patients. Higher recurre
Autor:
Patricia A. Thompson, Michelle Turner, Carolyn Mies, Jules Cohen, Caterina Vacchi-Suzzi, Alison Stopeck, Lea N. Baer, Christina Preece, Christy A. Russell, Rebecca Batiste, Julie Anne L Gemmill
Publikováno v:
Cancer Research. 81:PS5-37
Background: Identifying when to start CDK4/6 inhibitors or use chemotherapy in hormone receptor positive (HR+) metastatic breast cancer (MBC) remains challenging. The 21-gene Oncotype DX Breast Recurrence Score® test is validated to predict chemothe
Publikováno v:
Cancer Research. 81:2771-2771
In recent years, novel immunotherapy strategies have shown remarkable results in treating various advanced cancers. The efficacy of immunotherapeutics has been dictated by the dynamic and spatially heterogeneous tumor microenvironment (TME) which inc
Publikováno v:
Cancer Research. 79:3316-3316
Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition syndrome, caused primarily by germline pathogenic TP53 variants and associated with a very high lifetime cancer risk which reaches approximately 100% by age 60 years. Individua
Autor:
Masakazu Toi, Zhipeng Wang, Kazuharu Shimizu, Norikazu Masuda, Takayuki Ueno, Yoshiki Mikami, Fumiaki Sato, Akira Myomoto, Satoko Takizawa, Gozoh Tsujimoto
Publikováno v:
Cancer Research. 72:P5-10
[Background and Aim] Although Trastuzumab has been used for HER2(+) breast cancer, the treatment response of Trastuzumab therapy depends on unknown mechanisms among individual cases. In order to avoid unnecessary adverse events and to lighten financi
Autor:
Min-Hsien Wu, Siou-Ru Ye, Hung-Ming Wang, Ting-Hsiuan Yeh, Jason Chia-Hsun Hsieh, Jane Ying-Chieh Lee, Yung-Chang Lin, Nina Ming-Jung Lin
Publikováno v:
Cancer Research. 77:3790-3790
Background: Circulating tumor cell (CTC) has been prognostic and predictive in numerous types of cancer; however, its role in early diagnosis of relapse remains unclear. Methods: Eighty-six patients were prospectively enrolled between March 2015 and
Autor:
Lei Lei, Tzu-Pin Lu, Zi-Yan Yang, Xian-Yuan Miao, Xiao-jia Wang, Hung-Chun Skye Cheng, Han-Ching Chan, Jia-Huan Huang
Publikováno v:
Cancer Research. 81:PS6-51
Purpose: Dutch clinical risk criteria (low-risk definition: age > 35 years and (grade 1 with tumor ≤3cm, grade 2 with tumor ≤2cm, or grade 3 with tumor ≤1cm) have been used to stratify the benefit of MammaPrint and Oncotype DX for the decision-
Publikováno v:
Cancer Research. 81:PS2-12
Background Oncotype Dx Recurrence Score (ODX-RS) is a 21-gene assay used to predict recurrence in early stage breast cancer and guide chemotherapy decisions. Invasive lobular carcinomas (ILC) represent approximately 10-15% of all breast cancers. Many
Autor:
Jane Wei, Jodi M. Carter, Laila Khazai, Laura J. van't Veer, Molly Klein, Gregor Krings, Dina Kokh, Kimberly Cole, Yunn-Yi Chen, Lamorna Brown-Swigart, Ronald Balassanian, Sara J. Venters, Laura J. Esserman, Bev Parker, Amy L. Delson, Christina Yau, Sunati Sahoo, W. Fraser Symmans, Denise M. Wolf
Publikováno v:
Cancer Research. 80:P6-10
Background: The I-SPY 2 TRIAL enrolls women with locally advanced, molecular high-risk breast cancer. An integrated Residual Cancer Burden (iRCB), based on MRI volume change through treatment, is used to predict pathologic complete response (pCR) in
Autor:
Juan Fernando Arango arteaga, Jairo Legaspi Folgueira, Maria Purificacion Martínez del Prado, Maria Angeles Sala Gonzalez, María Teresa Abad Villar, Laura Sande Sardina, Fernando Pikabea Diaz, Borja Lopez De San Vicente, Maria Teresa Perez hoyos, Covadonga Figaredo Berjano, Maitane Nuño Escolástico, Patricia Novas Vidal, Ane Zumárraga Cuesta, Elena Calvo, Maria Lopez Santillan
Publikováno v:
Cancer Research. 80:P3-14
Introduction: Oncotype DX (ODX) Recurrence Score (RS) is a gene-expression assay that provides prognostic and predictive information in hormonal-receptor positive (HR +), human epidermal growth factor receptor 2 negative (HER2-), axilary lymph node n